The research of Dr. Sévigny’s team focusses on the functions of extracellular nucleotides, exerted through the activation of P2 receptors, with an emphasis on the enzymes that regulate their concentrations at the cell surface.  Dr. Sévigny and his team have also identified, cloned and characterized six new genes, including the first member of a new family encoding enzymes called NTPDases.  His team is interested in several biological functions including the regulation of inflammation in response to pathogenic determinants, the migration of immune cells, the functions of leukocytes, the contraction of smooth muscles, and in particular the regulation of inflammation of the intestine with an emphasis on epithelial cells and on a potential treatment for inflammatory bowel disease.

Dr Sévigny’s team uses animal models with KO mice as well as methods of cell biology (murine and human primary cells), pharmacology, biochemistry and immunology.

CHUL
2705, boulevard Laurier
T1-49
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 46319
+1 418-654-2765
jean.sevigny@crchudequebe...

Latest news

293 entries « ‹ 28 of 30 › »

Braun N, Sévigny J, Robson SC, Enjyoji K, Guckelberger O, Hammer K, Di Virgilio F, Zimmermann H

Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain

Journal Article

Eur J Neurosci, 12 (12), 2000.

Abstract | Links:

Leclerc MC, Grondin G, Gendron FP, Sévigny J, Beaudoin AR

Identification, characterization, and immunolocalization of a nucleoside triphosphate diphosphohydrolase in pig liver

Journal Article

Arch Biochem Biophys, 377 (2), 2000.

Abstract | Links:

Imai M, Takigami K, Guckelberger O, Enjyoji K, Smith RN, Lin Y, Csizmadia E, Sévigny J, Rosenberg RD, Bach FH, Robson SC

Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection

Journal Article

Mol Med, 5 (11), 1999.

Abstract | Links:

Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Esch JS, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD

Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation

Journal Article

Nat Med, 5 (9), 1999.

Abstract | Links:

Koziak K, Sévigny J, Robson SC, Siegel JB, Kaczmarek E

Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes

Journal Article

Thromb Haemost, 82 (5), 1999.

Abstract | Links:

Imai M, Kaczmarek E, Koziak K, Sévigny J, Goepfert C, Guckelberger O, Csizmadia E, Schulte am Esch J, Robson SC

Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells

Journal Article

Biochemistry, 38 (41), 1999.

Abstract | Links:

Schulte am Esch J, Sévigny J, Kaczmarek E, Siegel JB, Imai M, Koziak K, Beaudoin AR, Robson SC

Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity

Journal Article

Biochemistry, 38 (8), 1999.

Abstract | Links:

Kittel A, Kaczmarek E, Sevigny J, Lengyel K, Csizmadia E, Robson SC

CD39 as a caveolar-associated ectonucleotidase

Journal Article

Biochem Biophys Res Commun, 262 (3), 1999.

Abstract | Links:

Benrezzak O, Grondin G, Sévigny J, Gendron FP, Rousseau E, D'Orléans-Juste P, Beaudoin AR

Identification and immunolocalization of two isoforms of ATP-diphosphohydrolase (ATPDase) in the pig immune system

Journal Article

Arch Biochem Biophys, 370 (2), 1999.

Abstract | Links:

Beaudoin AR, Sévigny J, Gendron FP, St George M, Leclerc MC

Prevention and reversal of thrombotic and inflammatory processes

Journal Article

Emerging therapeutic targets, 2 (1), 1998.

| Links:

293 entries « ‹ 28 of 30 › »
Signaler des ajouts ou des modifications

Active projects

  • A recombinant soluble NTPDase8 as a novel biological treatment for inflammatory bowel disease, from 2021-10-01 to 2026-09-30
  • Ectonucleotidases and Extracellular Nucleotides in Smooth Muscle Cell Contraction, from 2023-04-01 to 2028-03-31
  • Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2025-06-30
  • Scaling up the production of recombinant human NTPDase8 in CHO expression system for in vivo testing, from 2023-09-01 to 2024-03-31

Recently finished projects

  • A novel approach to treating inflammatory bowel diseases through the blocking of P2Y6 receptors, from 2018-04-01 to 2023-03-31
  • Role of NTPDase1 and Extracellular Nucleotides in Smooth Muscle Cell Contraction., from 2016-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery